Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 5
1995 2
1996 5
1997 5
1998 6
1999 6
2000 4
2001 6
2002 6
2003 3
2004 5
2005 2
2006 5
2007 1
2008 4
2009 5
2010 4
2011 2
2012 2
2013 5
2014 2
2015 5
2016 6
2017 6
2018 13
2019 8
2020 7
Text availability
Article attribute
Article type
Publication date

Search Results

119 results
Results by year
Filters applied: . Clear all
Page 1
The lack of BTK does not impair monocytes and polymorphonuclear cells functions in X-linked agammaglobulinemia under treatment with intravenous immunoglobulin replacement.
Cavaliere FM, Prezzo A, Bilotta C, Iacobini M, Quinti I. Cavaliere FM, et al. PLoS One. 2017 Apr 19;12(4):e0175961. doi: 10.1371/journal.pone.0175961. eCollection 2017. PLoS One. 2017. PMID: 28422989 Free PMC article.
The lack of BTK in X-linked agammaglobulinemia (XLA) patients does not affect monocytes and polymorphonuclear cells (PMN) phenotype and functions. ...Intravenous immunoglobulin (IVIg) infusion exerted an anti-i …
The lack of BTK in X-linked agammaglobulinemia (XLA) patients does not affect monocytes and polymorpho
Azole antifungals and new targeted therapies for hematological malignancy.
Lindsay J, Teh BW, Micklethwaite K, Slavin M. Lindsay J, et al. Curr Opin Infect Dis. 2019 Dec;32(6):538-545. doi: 10.1097/QCO.0000000000000611. Curr Opin Infect Dis. 2019. PMID: 31688198 Review.
RECENT FINDINGS: New targeted therapies for hematological malignancy include chimeric antigen receptor T cells (CAR T cells), Bi-specific T-cell Engager (BiTE) blinatumomab, and the antibody-drug conjugate (ADC) of calicheamicin inotuzumab ozogamicin for acute lymph …
RECENT FINDINGS: New targeted therapies for hematological malignancy include chimeric antigen receptor T cells (CAR T cells), …
How I manage patients with hairy cell leukaemia.
Thompson PA, Ravandi F. Thompson PA, et al. Br J Haematol. 2017 May;177(4):543-556. doi: 10.1111/bjh.14524. Epub 2017 Feb 1. Br J Haematol. 2017. PMID: 28146266 Review.
Patients with hairy cell leukaemia (HCL) have highly favourable outcomes after purine analogue therapy. However, most patients subsequently relapse and require re-treatment. ...HCL variant and the IGHV4-34 molecular variant of HCL lack BRAF mutation and have …
Patients with hairy cell leukaemia (HCL) have highly favourable outcomes after purine analogue therapy. However, most patients subseq …
The Role of Bruton's Tyrosine Kinase in Immune Cell Signaling and Systemic Autoimmunity.
Rip J, Van Der Ploeg EK, Hendriks RW, Corneth OBJ. Rip J, et al. Crit Rev Immunol. 2018;38(1):17-62. doi: 10.1615/CritRevImmunol.2018025184. Crit Rev Immunol. 2018. PMID: 29717662 Review.
Bruton's tyrosine kinase (BTK) is an intracellular signaling molecule first identified as the molecule affected in X-linked agammaglobulinemia (XLA) patients, who almost completely lack peripheral B cells and serum immunoglobulins. …
Bruton's tyrosine kinase (BTK) is an intracellular signaling molecule first identified as the molecule affected in X-linked
Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib.
Sun B, Shah B, Fiskus W, Qi J, Rajapakshe K, Coarfa C, Li L, Devaraj SG, Sharma S, Zhang L, Wang ML, Saenz DT, Krieger S, Bradner JE, Bhalla KN. Sun B, et al. Blood. 2015 Sep 24;126(13):1565-74. doi: 10.1182/blood-2015-04-639542. Epub 2015 Aug 7. Blood. 2015. PMID: 26254443 Free PMC article.
Here, we demonstrate that treatment with the BET protein bromodomain antagonist (BA) JQ1 attenuates MYC and cyclin-dependent kinase (CDK)4/6, inhibits the nuclear RelA levels and the expression of NF-κB target genes, including Bruton tyrosine kinase (BTK) in MCL …
Here, we demonstrate that treatment with the BET protein bromodomain antagonist (BA) JQ1 attenuates MYC and cyclin-dependent kinase ( …
p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma.
Giordano F, Vaira V, Cortinovis D, Bonomo S, Goedmakers J, Brena F, Cialdella A, Ianzano L, Forno I, Cerrito MG, Giovannoni R, Ferri GL, Tasciotti E, Vicent S, Damarco F, Bosari S, Lavitrano M, Grassilli E. Giordano F, et al. J Exp Clin Cancer Res. 2019 Jun 14;38(1):260. doi: 10.1186/s13046-019-1199-7. J Exp Clin Cancer Res. 2019. PMID: 31200752 Free PMC article.
BTK-TKIs were more effective than EGFR-TKIs in decreasing cancer cell viability and significantly impaired cell proliferation and clonogenicity. ...Notably, these patients are not eligible for EGFR-TKIs-based therapy due to a lack of EGFR mutation. The
BTK-TKIs were more effective than EGFR-TKIs in decreasing cancer cell viability and significantly impaired cell proliferation
Delayed diagnosis in X-linked agammaglobulinemia and its relationship to the occurrence of mutations in BTK non-kinase domains.
Carrillo-Tapia E, García-García E, Herrera-González NE, Yamazaki-Nakashimada MA, Staines-Boone AT, Segura-Mendez NH, Scheffler-Mendoza SC, O Farrill-Romanillos P, Gonzalez-Serrano ME, Rodriguez-Alba JC, Santos-Argumedo L, Berron-Ruiz L, Sanchez-Flores A, López-Herrera G. Carrillo-Tapia E, et al. Expert Rev Clin Immunol. 2018 Jan;14(1):83-93. doi: 10.1080/1744666X.2018.1413349. Epub 2017 Dec 11. Expert Rev Clin Immunol. 2018. PMID: 29202590
BACKGROUND: X-linked agammaglobulinemia (XLA) is characterized by the absence of immunoglobulin and B cells. Patients suffer from recurrent bacterial infections from early childhood, and require lifelong immunoglobulin replacement ther
BACKGROUND: X-linked agammaglobulinemia (XLA) is characterized by the absence of immunoglobulin and B cells. Pat …
Bruton's tyrosine kinase separately regulates NFkappaB p65RelA activation and cytokine interleukin (IL)-10/IL-12 production in TLR9-stimulated B Cells.
Lee KG, Xu S, Wong ET, Tergaonkar V, Lam KP. Lee KG, et al. J Biol Chem. 2008 Apr 25;283(17):11189-98. doi: 10.1074/jbc.M708516200. Epub 2008 Feb 13. J Biol Chem. 2008. PMID: 18276597 Free article.
Stimulation of B cells with TLR9 ligand CpG oligodeoxynucleotide (ODN) leads to transient phosphorylation of Btk, and in the absence of Btk, TLR9-induced proliferation of B cells is impaired. ...TLR9 signaling also leads to the activation of NFk …
Stimulation of B cells with TLR9 ligand CpG oligodeoxynucleotide (ODN) leads to transient phosphorylation of Btk, and in the a …
Rapid Multiplexed Proteomic Screening for Primary Immunodeficiency Disorders From Dried Blood Spots.
Collins CJ, Chang IJ, Jung S, Dayuha R, Whiteaker JR, Segundo GRS, Torgerson TR, Ochs HD, Paulovich AG, Hahn SH. Collins CJ, et al. Front Immunol. 2018 Dec 4;9:2756. doi: 10.3389/fimmu.2018.02756. eCollection 2018. Front Immunol. 2018. PMID: 30564228 Free PMC article.
Despite the fact that effective, curative treatments are available with optimal clinical outcomes when diagnosed early, newborn screening does not exist for the majority of these diseases due to the lack of detectable, specific biomarkers or validated methods for po …
Despite the fact that effective, curative treatments are available with optimal clinical outcomes when diagnosed early, newborn scree …
[Gene diagnosis of X-linked agammaglobulinemia].
Wang XC, Wang Y, Kanegane H, Toshio M, Yu YH. Wang XC, et al. Zhonghua Er Ke Za Zhi. 2005 Jun;43(6):449-52. Zhonghua Er Ke Za Zhi. 2005. PMID: 16053733 Chinese.
OBJECTIVE: X-linked agammaglobulinemia (XLA) is the most common disorder among primary immunodeficiency diseases, which is caused by mutations in the cytoplasmic Bruton's tyrosine kinase (BTK) gene, characterized by lack of mature, circulating B …
OBJECTIVE: X-linked agammaglobulinemia (XLA) is the most common disorder among primary immunodeficiency diseases, which is cau …
119 results
Jump to page
Feedback